Radiopharm Theranostics Ltd

Radiopharm Theranostics has a market capitalization of AUD 55.88 million with a current share price of AUD 4.73, implying a 298% discount to the mean analyst price target of AUD 14.38. The company has no dilution risk in the near term, with basic and diluted shares outstanding aligned at 11.81 million shares. However, liquidity risk remains unassessed due to incomplete balance sheet data and absence of going-concern disclosures.

Profitability metrics are unavailable due to lack of financial statement data. As a biotechnology company in the pharmaceuticals industry, the firm would typically be evaluated using R&D intensity, preclinical/clinical pipeline progress, and regulatory milestones rather than traditional margin metrics. The absence of revenue, EBITDA, or ROIC data prevents direct comparison to industry medians.

The company's geographic exposure is concentrated in Australia, with no disclosed international operations. Segment data is unavailable, but as a radiopharmaceutical developer, the business would likely focus on oncology and nuclear imaging applications. No revenue concentration data is available to assess customer or product diversification.

Revenue growth trajectory is indeterminable due to lack of historical financials. Analysts have assigned a mean recommendation of 2.0 (buy rating), with three buy ratings and no strong buy or hold ratings. The significant price target range (AUD 13.00 to 16.00) suggests high uncertainty about the company's valuation potential.

Key risk factors include unassessed liquidity risk and lack of financial transparency. The absence of balance sheet data prevents evaluation of debt levels, cash reserves, or working capital position. No dilution risk is currently indicated, but the lack of capital structure data makes future financing needs indeterminable.

Recent events include the publication of analyst price targets and recommendations, but no material filings or earnings reports were identified in the source data. The company's development-stage status implies that regulatory approvals and clinical trial outcomes will be critical near-term catalysts.

Revenue A$3.6M, +1 114,3% YoY; Operating income +19,1% YoY.

• ▍Revenue A$3.6M, +1 114,3% YoY
• ▍Operating income +19,1% YoY
• ▍Net income +23,4% YoY
• ▍Free cash flow +20,2% YoY
• ▍Net margin -1010.2%